Mode
Text Size
Log in / Sign up

Systematic review and meta-analysis assesses SWDS diagnostic accuracy for MASLD liver inflammation grading

Systematic review and meta-analysis assesses SWDS diagnostic accuracy for MASLD liver inflammation g…
Photo by Navy Medicine / Unsplash
Key Takeaway
Note SWDS diagnostic performance for MASLD inflammation grading is influenced by fibrosis burden.

This systematic review and diagnostic test accuracy meta-analysis evaluates the Shear-wave dispersion slope (SWDS) for detecting and grading biopsy-proven liver inflammation in Metabolic dysfunction-associated steatotic liver disease (MASLD). The analysis pooled data from 1168 patients to report sensitivity, specificity, and area under the curve values across different inflammation grades. Authors note that diagnostic accuracy is influenced by fibrosis burden, particularly for severe inflammation, which limits generalizability.

For detecting grade ≥A1 inflammation, sensitivity was 0.75 (95% CI: 0.71-0.79) and specificity was 0.87 (95% CI: 0.80-0.92). The sAUC for this grade was 0.886. For grade ≥A2, sensitivity was 0.78 (95% CI: 0.75-0.81) and specificity was 0.77 (95% CI: 0.72-0.81), with an sAUC of 0.856. For grade A3, sensitivity was 0.64 (95% CI: 0.58-0.70) and specificity was 0.79 (95% CI: 0.76-0.81), with an sAUC of 0.847.

Diagnostic odds ratios were 20.08 (95% CI: 11.35-35.50) for grade ≥A1, 11.87 (95% CI: 8.72-16.15) for grade ≥A2, and 6.69 (95% CI: 4.95-9.04) for grade A3. High-grade fibrosis (F2-F4) contributed significantly to heterogeneity in sensitivity, with an R²_Se of 75.1% (p < 0.001). Safety data were not reported. The authors conclude that SWDS demonstrates good diagnostic performance for detecting and grading biopsy-proven liver inflammation in MASLD, particularly for ≥A1 and ≥A2 activity, but caution that accuracy is influenced by fibrosis burden.

Study Details

Study typeMeta analysis
Sample sizen = 1,168
EvidenceLevel 1
PublishedMay 2026
View Original Abstract ↓
OBJECTIVE: Shear-wave dispersion slope (SWDS), a viscosity-related ultrasound biomarker, is increasingly used to evaluate hepatic inflammation in metabolic dysfunction-associated steatotic liver disease (MASLD). We aimed to synthesize the diagnostic performance of SWDS for detecting and grading biopsy-proven liver inflammation. METHODS: We performed a systematic review and diagnostic test accuracy meta-analysis of studies using liver biopsy as the reference standard. The primary analysis used a bivariate random-effects model (Hierarchical summary receiver operating characteristic curve, HSROC) to jointly pool sensitivity and specificity, display the summary operating point with confidence and prediction regions, and compute the summary area under the curve (sAUC). Positive and negative likelihood ratios and the diagnostic odds ratio (DOR) were derived from the model-based summaries. Heterogeneity was described by logit-scale between-study variances and HSROC prediction regions, prespecified study-level covariates were assessed with bivariate meta-regression. RESULTS: Seven studies including 1168 patients met inclusion criteria. Summary sensitivity and specificity were 0.75 (95% CI: 0.71-0.79) and 0.87 (95% CI: 0.80-0.92) for grade ≥A1, 0.78 (95% CI: 0.75-0.81) and 0.77 (95% CI: 0.72-0.81) for grade ≥A2, and 0.64 (95% CI: 0.58-0.70) and 0.79 (95% CI: 0.76-0.81) for grade A3. The corresponding sAUCs were 0.886, 0.856, and 0.847. DORs were 20.08 (95% CI: 11.35-35.50), 11.87 (95% CI: 8.72-16.15), and 6.69 (95% CI: 4.95-9.04) for ≥A1, ≥A2, and A3, respectively. Meta-regression analysis identified high-grade fibrosis (F2-F4) as a major contributor to heterogeneity in sensitivity (R²_Se 75.1%, p < 0.001). CONCLUSION: SWDS demonstrates good diagnostic performance for detecting and grading biopsy-proven liver inflammation in MASLD, particularly for ≥A1 and ≥A2 activity. However, its accuracy is influenced by fibrosis burden, especially for severe inflammation, and should be interpreted in this context.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.